Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist approved for treatment of type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). The peptide is 94% structurally similar to human GLP-1 but with modifications that provide a half-life of approximately 7 days, allowing once-weekly dosing. Semaglutide enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system effects. Clinical trials have demonstrated significant HbA1c reductions in diabetes and substantial weight loss (15-17% in obesity trials), along with cardiovascular benefits. It represents a major advancement in metabolic disease treatment.
| Research Status | FDA approved |
|---|---|
| Half-Life | ~7 days |
| Administration | Subcutaneous injection |
| Typical Dosage | 0.25-2.4 mg weekly |
| Molecular Weight | 4,113.6 Da |
| Molecular Formula | C187H291N45O59 |
GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves insulin sensitivity.
All information is presented for Research Use Only (RUO). Not medical advice.